MTOR and non-small cell lung carcinoma: In addition, NSCLC cell lines with higher Metabolism Scores were found to be vulnerable to the following drugs (Figure 8G): platinum compounds (cisplatin), alkylating agent (dacarbazine), cyanoaziridine derivative (imexon), PARP inhibitor (olaparib), PI3K/mTOR inhibitors (rapamycin, temsirolimus, everolimus and idelalisib) and hormone drugs (calusterone and raloxifene).